Advertisement
"This substantial funding from blue-chip biomedical investors is a firstin our industry and a testament to the promise of ViewRay's technology to helpcancer patients. More importantly, it allows us to accelerate the developmentof our system, the first device to promise real-time volumetric imagingsimultaneous with radiation treatment" explained ViewRay CEO William Wells.
Advertisement
The ViewRay Renaissance(TM) System 1000 technology was invented by JamesF. Dempsey, Ph.D., associate professor in the Department of RadiationOncology at the University of Florida and has been exclusively licensed by theCompany from the University of Florida. Proceeds from the Series B financingwill be used to further build the ViewRay Incorporated team and manufactureand validate advanced prototypes of the Renaissance(TM) System 1000.
About OrbiMed Advisors LLC
OrbiMed is the world's largest healthcare-dedicated investment firm, withover $6 billion in assets under management. OrbiMed's investment advisorybusiness was founded in 1989 with a vision to invest across the spectrum ofhealthcare companies: from private start-ups to large multinational companies.OrbiMed manages the Caduceus Private Investments series of venture capitalfunds and a family of public equity investment funds.Web site: http://www.orbimed.com
About Fidelity Biosciences
We are a division of Fidelity Investments, one of the world's leadingproviders of financial services. For more than 30 years, Fidelity Investmentshas been a significant presence in the venture capital and private equityindustry, investing the firm's own capital since 1969. This provides us withthe flexibility, and capabilities of traditional venture capital firms whileeliminating the additional pressures of fundraising. The result is a clearfocus on building long-term value for Fidelity, our management partners, andco-investors.
Web site: http://www.fidelitybiosciences.com
About Aisling Capital
Aisling Capital is a dedicated life sciences private equity firm with US$1 billion under management. Headquartered in New York, Aisling Capitalinvests in both private and public companies utilizing a wide variety ofinvestment structures. The Aisling Capital team's combination of clinical,operational and financial experience allows the firm to identify, execute andrealize investments across the life sciences industry.
Web site: http://www.aislingcapital.com
About Kearny Venture PartnersWith over $330 million in capital under management, Kearny Venture Partners isa venture capital firm exclusively focused on healthcare products. We believethat the opportunity for entrepreneurs to devise innovative solutions inhealthcare has never been greater. Significant unmet needs in healthcarecontinue to persist, representing large potential market opportunities forsafe and effective products. As the molecular basis of disease is increasinglyunraveled, new opportunities for intervention emerge. Novel therapies can andwill displace incumbent products.
Web site: http://www.kearnyvp.com
SOURCE ViewRay Incorporated
